Drug Database
DR

droperidol (Dridol / Xomolix)

✓ Approved

Kyowa Kirin Co., Ltd. · DRD2 · 小分子

什么是 droperidol?

droperidol 是一种小分子,由Kyowa Kirin Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Dridol, Xomolix
公司Kyowa Kirin Co., Ltd.
药物类别小分子
分子靶点DRD2
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

droperidol 作用于 1 个分子靶点:

DRD2dopamine receptor D2 (D2DR, D2R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

droperidol 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresProphylaxis of nausea and vomiting✓ Approved

相关研究文献

PubMedJournal of clinical psychopharmacology2026-11-18

The Role of Droperidol in the Management of Acute Agitation: A Comprehensive Review.

Gupta Srajan S, Patel Malav M, Jeelugu Sreshta S, Shah Hetansh H et al.

Acute behavioral disturbance accounts for ~1.7 million emergency department visits in the USA annually, with 83% involving an underlying serious mental illness. A 2001 FDA black box warning regarding QT prolongation reduced use of droperidol, a butyrophenone antipsychotic, but recent data challenge these concerns. We reviewed randomized controlled trials, systematic reviews, and observational studies from 2000 to 2025 assessing droperidol's efficacy and safety. Droperidol provides rapid, effective sedation, with onset within 3 to 10 minutes and median time to adequate sedation of 14 to 25 minutes. Sixty-four percent of patients achieved adequate sedation at 15 minutes with droperidol versus 25% to 35% with ziprasidone and 29% with lorazepam. QT prolongation occurred in 1.3% of 1009 patients, mostly those with pre-existing risk factors. Respiratory depression was less common with droperidol (12%) than with ziprasidone (36% to 39%) or lorazepam (48%). Droperidol-midazolam combinations achieved faster sedation and reduced need for rescue medications (41% vs. 62%). Droperidol-treated patients had shorter hospital stays. Large studies found negligible rates of torsades de pointes or extracardiac arrhythmias. Elderly and pediatric patients responded favorably to low-dose droperidol. The American College of Emergency Physicians now recommends droperidol as first-line treatment for severe agitation. Combined with benzodiazepines, droperidol shows synergistic effects and allows lower doses of both with fewer adverse effects. Recent evidence contradicts earlier FDA concerns, supporting droperidol as a safe, effective treatment for acute agitation. Its rapid onset, efficacy, safety profile, and operational benefits, including shorter ED stay, support its return to routine clinical practice.

PMID 43049443
阅读全文 →
PubMedChemical biology & drug design2026-11-18

Multomic Analysis of Sepsis Molecular Subtypes: Discovery of Candidate Biomarkers and Potential Drug Targets.

Yu Xiaomin X, Deng Yuqian Y, Song Qiang Q, Xu Xinyu X et al.

Sepsis exhibits significant heterogeneity, and molecular subtyping may help characterize this heterogeneity. Based on public transcriptomic and single-cell data from sepsis patients, this study used the NMF algorithm to classify patients into three molecular subtypes. Subtype C1 is characterized by metabolic disturbances and innate immune activation; subtype C2 is characterized by adaptive immune activation and has the highest survival rate (88.9%); subtype C3 is characterized by epigenetic dysregulation and the lowest observed 28-day survival proportion (73.8%). Machine learning identified four candidate subtype-associated genes-MMP8, KCNMA1, HPGD, and FAM102A-and the four-gene SVM classifier showed exploratory internal subtype separability (accuracy, 78.2%; one-vs-all AUCs, 0.894-0.928). Network pharmacology screening identified 113 traditional Chinese medicine compounds and two Western drugs. Single-cell analysis characterized the cell-type-specific expression patterns of these genes and identified exploratory expression-associated communication patterns. In vitro experiments showed that HPGD protein expression was increased in LPS-stimulated AML-12 cells, whereas treatment with droperidol or Ganoderma lucidum extract was associated with lower HPGD expression levels. This study proposes a potential molecular subtyping framework and prioritizes candidate biomarkers and compounds for further validation.

PMID 43046592
阅读全文 →
PubMedAcademic emergency medicine : official journal of the Society for Academic Emergency Medicine2026-11-05

Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department.

O'Brien Joseph J, Patel Mayher M, Brown Joseph J, Tucker Ryan R et al.

Cannabinoid hyperemesis syndrome (CHS) is an increasingly frequent emergency department (ED) presentation. Although ondansetron is commonly used, emerging evidence suggests haloperidol and droperidol may provide more effective symptom control. Robust comparative effectiveness data, particularly regarding short-term ED recidivism, remain limited. We conducted a multicenter retrospective cohort study using the TriNetX Research Network from 2014 to 2024. Adults presenting to the ED with vomiting-related and cannabis-related ICD-10 diagnoses who received haloperidol, droperidol, or ondansetron during the index encounter were included. Patients with alternative causes of vomiting or major confounding conditions were excluded. Propensity-score matching was performed for three pairwise comparisons: haloperidol versus ondansetron, droperidol versus ondansetron, and droperidol versus haloperidol. The primary outcome was 72-h ED recidivism. Secondary outcomes included 72-h hospital admission, 7-day ED recidivism, and coded adverse events. Multivariable Cox proportional hazards modeling evaluated independent predictors of 72-h ED recidivism. After matching, haloperidol was associated with lower 72-h ED recidivism compared with ondansetron (8.2% vs. 15.1%; OR 0.50, 95% CI 0.41-0.62; p < 0.0001). Droperidol was also associated with lower 72-h ED recidivism compared with ondansetron (7.4% vs. 14.0%; OR 0.49, 95% CI 0.32-0.76; p = 0.0014). Droperidol and haloperidol did not differ significantly in 72-h ED recidivism (7.5% vs. 9.8%; OR 0.75, 95% CI 0.47-1.20; p = 0.23). In the multivariable model, haloperidol (HR 0.62, 95% CI 0.49-0.79) and droperidol (HR 0.68, 95% CI 0.56-0.83) were independently associated with lower return risk, whereas ondansetron was not. Coded adverse events were rare across all groups. In this large multicenter cohort, haloperidol and droperidol were associated with lower short-term ED recidivism than ondansetron among adults meeting a suspected CHS phenotype. These findings support prospective studies evaluating haloperidol and droperidol for ED management of CHS, including optimal dosing, route, medication sequencing, discharge treatment, and safety monitoring.

PMID 42983225
阅读全文 →
PubMedBMC anesthesiology2026-10-20

Comparison of dexmedetomidine and droperidol-fentanyl for asleep-awake-asleep techniques in awake craniotomy anesthesia: a randomized controlled study.

Yang Xiaomei X, Qu Dongdong D, Ren Yiyan Y, Guo Yaqiu Y et al.

In this study, we aimed to compare dexmedetomidine with droperidol-fentanyl during the intraoperative awakening phase of awake craniotomy (AC), focusing on wake-up time. We conducted a single-center randomized controlled trial in China from January 2018 to December 2018. Patients aged 36-60 years, with American Society of Anesthesiologists physical status I-II, scheduled for brain glioma resection, were screened for eligibility; 61 were randomized, and 60 were included in the final analysis. The patients were randomized to either the dexmedetomidine group (intravenous loading dose of dexmedetomidine 0.5 µg·kg- 1 after discontinuation of propofol and remifentanil, followed by a maintenance infusion of dexmedetomidine 0.3-0.5 µg·kg- 1·h- 1) or the droperidol-fentanyl group (intravenous loading doses of fentanyl 2 µg·kg- 1 and droperidol 5 mg after discontinuation of propofol and remifentanil, followed by continuous maintenance infusions of fentanyl 2 µg·kg- 1·h- 1 and droperidol 0.1 mg·kg- 1·h- 1). A wake-up assessment was performed during maintenance of the assigned study regimen. The primary outcome measure was wake-up time. Secondary outcomes included the Observer's Assessment of Alertness/Sedation (OAA/S) scale, Numerical Rating Scale (NRS), eloquent brain area mapping status, vital signs, and adverse events. Baseline characteristics were comparable between the groups. Compared with the droperidol-fentanyl group, the dexmedetomidine group had lower mean arterial pressure at T4-T7, lower heart rate at T1-T4 and T7, and a shorter wake-up time, with a between-group difference of 3.5 min (95% CI, 1.95 to 5.05; P < 0.001). No statistically significant differences were detected in OAA/S scores at wake-up (T2), NRS scores, eloquent area mapping status, or adverse events between the groups. No statistically significant differences were detected in OAA/S scores at wake-up or intraoperative brain mapping performance between the two groups. The dexmedetomidine regimen was associated with a shorter measured wake-up time. The Chinese Clinical Trial Registry (ChiCTR1800014329) was retrospectively registered on 6 January 2018.

PMID 42897460
阅读全文 →
PubMedClinical neuropharmacology2026-09-24

Cytotoxic Lesion of the Corpus Callosum After Hospital-Administered Intravenous Fentanyl for Trigeminal Neuralgia: A Case Report and Focused Review.

Benito-León Julián J

Fentanyl-associated neurotoxicity is increasingly recognized across illicit, inhalational, transdermal, pediatric, and delayed posthypoxic exposures, but isolated splenial CLOCC after hospital-administered intravenous fentanyl has not been well characterized. This is a single-patient case report with a focused review of fentanyl-associated neurotoxic syndromes and proposed mechanisms. A 41-year-old woman with trigeminal neuralgia presented with severe facial pain. After droperidol, metoclopramide, and metamizole failed to control symptoms, intravenous fentanyl (75 μg) was administered. Soon afterward, she developed dizziness, nausea, vomiting, left-sided paresthesias, hypoesthesia, and mild weakness. Initial computed tomography was unrevealing, and cerebrospinal fluid findings were normal. Brain magnetic resonance imaging (MRI) obtained 8 days later showed a 6-mm midline splenial lesion that was hyperintense on T2-weighted and FLAIR sequences, restricted on diffusion-weighted imaging, and nonenhancing, consistent with CLOCC. Follow-up MRI showed complete radiologic resolution, but serial assessments documented persistent deficits in the left upper and lower extremities, including impaired fine motor control, dysdiadochokinesia, arm and leg weakness, foot drag, and gait imbalance; somatosensory-evoked potentials showed mild dysfunction of the left lower-extremity pathway. Review of comparable fentanyl-associated cases shows a spectrum ranging from isolated callosal injury to diffuse, cerebellar, and delayed leukoencephalopathic phenotypes. This case expands the neuroimaging spectrum of fentanyl-associated brain injury and supports a toxic-metabolic pathogenesis in which splenial CLOCC may represent a focal manifestation of broader opioid-related white-matter vulnerability.

PMID 42784751
阅读全文 →
PubMedMethods and protocols2026-09-23

Comparison of the Utility of Amplitude-Spectral and Coherence Features of Psychotropic Drugs' Action on ECoG Signal for Pharmaco-EEG Based Drug Screening in Rats.

Sysoev Yuriy I YI, Kurmazov Nikita S NS, Shitc Darya D DD, Okovityi Sergey V SV

A naive Bayesian classifier (NBC) combined with principal component analysis (PCA) effectively differentiates the dose-dependent effects of certain groups of psychoactive drugs based on their impact on the amplitude-spectral characteristics of electrocorticograms (ECoG) in rats. This approach has been shown to be useful for pharmacological screening of agents with unknown or poorly understood activity. Despite previously obtained optimistic results, classification determination for some drugs was inaccurate, necessitating the search for possible ways to improve the predictive effectiveness of the proposed algorithm. One possible approach would be to use as input quantitative data not only the impact of the psychoactive drugs studied on the amplitude-spectral characteristics of ECoG but also connectivity changes, including the average coherence power of different pairs of leads. The aim of this study was to compare the accuracy of NBC in classifying the pharmacological mechanism of action of agents with well-known mechanisms (test set) using pharmaco-EEG data on changes in the amplitude-spectral characteristics of ECoG, coherence, and the combined use of two data sets. Materials and methods. Experiments were performed on Wistar rats with chronically implanted ECoG electrodes. The training set, relative to which the effects of the pharmacological agents from the test set were classified, were the matrices of effects of 12 pharmacological agents: the NMDA antagonist dizocilpine, the D2/D3 antagonists haloperidol and sulpiride, the M-anticholinergic tropicamide, the H1/5HT2A receptor blocker hydroxyzine, the acetylcholinesterase inhibitor galantamine, the alpha-2 adrenergic agonist dexmedetomidine, the alpha-2 adrenergic antagonist atipamezole, the adenosine receptor blocker caffeine and the GABA-mimetics aminophenylbutyric acid (phenibut), bromdihydrochlorophenylbenzodiazepine (phenazepam) and 5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione. The test set included various drugs with tropism for the targets of the training set drugs: dopamine receptor antagonists chlorpromazine, droperidol, tiapride and raclopride, H1-histamine blockers diphenhydramine and promethazine, 5-HT2-receptor blockers ritanserin and glemenserin, acetylcholinesterase inhibitor ipidacrine, alpha2-adrenergic receptor antagonist yohimbine, alpha2-adrenergic agonists medetomidine and xylazine, GABA-mimetics 5-ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione and chloral hydrate. The analysis of the ECoG signal included the calculation of 132 amplitude-spectral characteristics and 75 coherence indicators, which, using the PCA, led to new integrative indicators used for further classification of the NBC. Results and discussion. For each drug in the test set, the median similarity probability with a particular group from the training set was calculated, which was used to assess the classification quality. It was found that, when using the amplitude-spectral characteristics of ECoG, the proposed methodological approach allows for the identification of the ECoG effects of several groups of psychoactive drugs, including D2/D3-dopamine, M-cholinergic, H1-histamine, and 5-HT2-serotonin receptor blockers, AChE inhibitors, GABA-mimetics, and alpha-2-adrenergic receptor agonists and antagonists. This approach enabled the correct classification of 18 of 24 groups in the test set. When using changes in coherence indices as the initial data, the classification accuracy also amounted to 18 of 24 groups. When combining the two data sets, the number of correctly identified NBC groups was 20 of 24 groups. When comparing the classification during training (confusion matrix), it was found that coherence data or adding coherence data to the data based on changes in amplitude-spectral characteristics leads to a statistically significant (p < 0.01 in both cases) increase in accuracy. Conclusions. The obtained data demonstrated high accuracy in classifying the pharmacological activity of the test sample drugs using any of the three compared approaches. Despite the lack of statistically significant differences between them, classification based on the combined dataset demonstrated a higher number of "correct" similarities. This allows us to recommend the approach based on combined data of drug effects on amplitude-spectral characteristics and coherence as the most promising for further studies using pharmaco-EEG screening.

PMID 42776676
阅读全文 →

注册免费账户还可查看另外 2211 篇文献

免费注册查看全部文献 →

了解更多droperidol